Captrust Financial Advisors Atea Pharmaceuticals, Inc. Transaction History

Captrust Financial Advisors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$5.33 - $8.18 $2,041 - $3,132	-383 Reduced 43.28%	502 $4,000
Q1 2022 May 16, 2022	BUY	$5.5 - $9.19 $341 - $569	62 Added 7.53%	885 $6,000
Q4 2021 Feb 14, 2022	BUY	$7.67 - $44.59 $6,312 - $36,697	823 New	823 $7,000
Q3 2021 Nov 16, 2021	SELL	$21.33 - $35.06 $554 - $911	-26 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$19.22 - $59.08 $422 - $1,299	22 Added 550.0%	26 $1,000
Q1 2021 May 17, 2021	BUY	$41.42 - $88.44 $165 - $353	4 New	4 $0

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $281M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.